• Bulletin du cancer · Nov 2012

    Review

    [Antiangiogenic agents: current limits in thoracic oncology].

    • Eric Dansin, Géraldine Lauridant, and Bachar Chahine.
    • CLCC Oscar-Lambret, département de cancérologie générale, Lille Cedex, France. e-dansin@o-lambret.fr
    • Bull Cancer. 2012 Nov 1;99(11):1083-91.

    AbstractAntiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.